The Indian pharmaceutical excipient landscape is witnessing a quiet but aggressive takeover by Accent Microcell (AML). In a financial year defined by strategic capital raises and massive capacity expansion, AML has posted a staggering 51% growth in quarterly sales, reaching ₹210 crore in the latest March 2026 results. This isn’t just a number; it is a declaration of market share capture.
While the broader pharmaceutical sector grapples with pricing pressures in generic formulations, Accent is sitting comfortably in the “bricks and mortar” of the pill—the excipients. With Microcrystalline Cellulose (MCC) as its primary weapon, the company is moving from a domestic player to a global powerhouse, servicing over 200+ customers and exporting to 36+ countries.
The intrigue lies in the execution. Management didn’t just talk about expansion; they funded it through a surgical combination of an IPO (₹78.40 crore) and a subsequent Rights Issue (₹39.77 crore). The “what next” is even more compelling: a massive jump from 9,600 MTPA to 24,000 MTPA total capacity is in the works. Investors are watching closely as the company transitions from a mid-sized manufacturer to a heavyweight in a fragmented market.
1. At a Glance – The Numbers That Scream Ambition
Accent Microcell is currently a high-octane growth engine disguised as a chemical company. The latest data reveals a Sales CAGR of 32% (TTM) and a Profit CAGR of 33% (TTM). This alignment of top-line and bottom-line growth is rare and indicates that the company isn’t just buying growth—it’s earning it through operational efficiency.
The Curiosity of the Pivot
The company is currently pivoting its product mix. While MCC remains the bread and butter (contributing ~85% of revenue), the real excitement is in the Unit 3 Kheda Phase 1 expansion. This unit targets premium excipients like Croscarmellose Sodium (CCS) and Sodium Starch Glycolate (SSG). Why does this matter? Because CCS is a “rapid disintegrant” that commands pricing 3.5 times higher than MCC.
The Scare Factor: Red Flags to Watch
Despite the stellar growth, the auditor’s lens reveals a few thorns:
- Debtor Days Spikes: Receivables have elongated from 80 days to 95 days. Management attributes this to liberal credit terms given to Indian MNCs to capture market share. While strategic, it ties up cash.
- Raw Material Volatility: Wood pulp is the primary input. Any global supply chain shock or spike in specialized pulp prices (which vary from ₹60 to ₹85/kg) directly hits the OPM.
- Asset Heavy Transition: The company is moving from a low-debt model to massive capex. Capital Work in Progress (CWIP) stands at a whopping ₹102 crore. If the ramp-up (expected at 60% in year one) stalls, the depreciation will eat into the PAT.
Can Accent Microcell maintain its 16% OPM while tripling its capacity? This is the billion-rupee question.
2. Introduction
Accent Microcell Limited is essentially the “hidden ingredient” company. If you have taken a medicine tablet recently, there is a high probability that the Microcrystalline Cellulose (MCC) holding that tablet together was manufactured by AML. Established in 2012, the company has mastered the art of manufacturing 22 different grades of MCC.
The business operates out of Gujarat, with two existing units in Pirana and Dahej (SEZ). The Dahej unit is particularly strategic, being an SEZ unit that provides significant tax benefits and caters primarily to the export market, which accounts for roughly 53% to 61% of total revenue.
In the last 24 months, the company has transformed its balance sheet. From a closely held public limited company in 2022 to an NSE SME listing in 2023, and a Rights Issue in 2025, AML is now a well-capitalized entity. This capital is being deployed into Unit 3 (Kheda), which is designed to make the company “fully integrated.” Instead of buying raw materials like CMC to make CCS, they will
